Company intelligence / Profile preview
NeoLogics Bioscience
Suzhou, Jiangsu, Chinaneologicsbio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 2
01
Overview
NeoLogics Bioscience has advanced its lead program NB002 into Phase 1 trials for metastatic solid tumors. Other candidates are in preclinical or IND-enabling stages, with a focus on best-in-class and first-in-class immunotherapies targeting novel immune checkpoints. Early data suggest superior anti-tumor efficacy compared to competitors in preclinical models.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodies (mAbs)Bispecific antibodies
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on NeoLogics Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeoLogics Bioscience.